Paclitaxel and cardiotoxicity
EA Perez
JCO Nov 1 1998: 3481–3482. [PDF]
	Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors
	M Markman, A Kennedy, K Webster, B Kulp, G Peterson, and J Belinson
	JCO Nov 1 1998: 3483–3485. [Abstract] [PDF]
	Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study
	EG Mansour, R Gray, AH Shatila, DC Tormey, MR Cooper, CK Osborne, and G Falkson
	JCO Nov 1 1998: 3486–3492. [Abstract] [PDF]
	Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
	CL Shapiro, PH Hardenbergh, R Gelman, D Blanks, P Hauptman, A Recht, DF Hayes, J Harris, and IC Henderson
	JCO Nov 1 1998: 3493–3501. [Abstract] [PDF]
	Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer
	M Ryberg, D Nielsen, T Skovsgaard, J Hansen, BV Jensen, and P Dombernowsky
	JCO Nov 1 1998: 3502–3508. [Abstract] [PDF]
	Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer
	BW Cooper, TJ Moss, AA Ross, J Ybanez, and HM Lazarus
	JCO Nov 1 1998: 3509–3517. [Abstract] [PDF]
	Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593
	MP Mehta, SP Tannehill, S Adak, L Martin, DG Petereit, H Wagner, JF Fowler, and D Johnson
	JCO Nov 1 1998: 3518–3523. [Abstract] [PDF]
	Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study
	J Treat, E Johnson, C Langer, C Belani, B Haynes, R Greenberg, R Rodriquez, P Drobins, W Miller, Jr, L Meehan, A McKeon, J Devin, R von Roemeling, and J Viallet
	JCO Nov 1 1998: 3524–3527. [Abstract] [PDF]
	Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer
	NC Choi, JE Herndon, 2nd, J Rosenman, RW Carey, CT Chung, S Bernard, L Leone, S Seagren, and M Green
	JCO Nov 1 1998: 3528–3536. [Abstract] [PDF]
	Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer
	JCO Nov 1 1998: 3537–3541. [Abstract] [PDF]
	Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study
	KH Bohuslavizki, S Klutmann, W Brenner, J Mester, E Henze, and M Clausen
	JCO Nov 1 1998: 3542–3549. [Abstract] [PDF]
	Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography
	CH Kao, SP ChangLai, PU Chieng, RF Yen, and TC Yen
	JCO Nov 1 1998: 3550–3555. [Abstract] [PDF]
	Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients
	R De Crevoisier, J Bourhis, C Domenge, P Wibault, S Koscielny, A Lusinchi, G Mamelle, F Janot, M Julieron, AM Leridant, P Marandas, JP Armand, G Schwaab, B Luboinski, and F Eschwege
	JCO Nov 1 1998: 3556–3562. [Abstract] [PDF]
	Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases
	A Pirzkall, J Debus, F Lohr, M Fuss, B Rhein, R Engenhart-Cabillic, and M Wannenmacher
	JCO Nov 1 1998: 3563–3569. [Abstract] [PDF]
	Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma
	HS Friedman, DM Kokkinakis, J Pluda, AH Friedman, I Cokgor, MM Haglund, DM Ashley, J Rich, ME Dolan, AE Pegg, RC Moschel, RE McLendon, T Kerby, JE Herndon, DD Bigner, and SC Schold, Jr
	JCO Nov 1 1998: 3570–3575. [Abstract] [PDF]
	Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03
	WU Shipley, KA Winter, DS Kaufman, WR Lee, NM Heney, WR Tester, BJ Donnelly, PM Venner, CA Perez, KJ Murray, RS Doggett, and LD True
	JCO Nov 1 1998: 3576–3583. [Abstract] [PDF]
	Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma
	JM Karjalainen, JK Kellokoski, MJ Eskelinen, EM Alhava, and VM Kosma
	JCO Nov 1 1998: 3584–3591. [Abstract] [PDF]
	Increased mortality after successful treatment for Hodgkin's disease
	MM Hudson, CA Poquette, J Lee, CA Greenwald, A Shah, X Luo, EI Thompson, JA Wilimas, LE Kun, and WM Crist
	JCO Nov 1 1998: 3592–3600. [Abstract] [PDF]
	Prognostic factors in the treatment of human immunodeficiency virus- associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases
	DJ Straus, J Huang, MA Testa, AM Levine, and LD Kaplan
	JCO Nov 1 1998: 3601–3606. [Abstract] [PDF]
	Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response
	V Gandhi, W Plunkett, CO Rodriguez, Jr, BJ Nowak, M Du, M Ayres, DF Kisor, BS Mitchell, J Kurtzberg, and MJ Keating
	JCO Nov 1 1998: 3607–3615. [Abstract] [PDF]
	Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia
	PA Evans, MA Short, RG Owen, AS Jack, PD Forsyth, CR Shiach, S Kinsey, and GJ Morgan
	JCO Nov 1 1998: 3616–3627. [Abstract] [PDF]
	Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
	A Craft, S Cotterill, A Malcolm, D Spooner, R Grimer, R Souhami, J Imeson, and I Lewis
	JCO Nov 1 1998: 3628–3633. [Abstract] [PDF]
	Constitutional WT1 mutations in Wilms' tumor patients
	L Diller, M Ghahremani, J Morgan, P Grundy, C Reeves, N Breslow, D Green, D Neuberg, J Pelletier, and FP Li
	JCO Nov 1 1998: 3634–3640. [Abstract] [PDF]
	Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study
	MB Harris, P Gieser, AM Goorin, A Ayala, SJ Shochat, WS Ferguson, T Holbrook, and MP Link
	JCO Nov 1 1998: 3641–3648. [Abstract] [PDF]
	Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer
	DR Miller, GT Anderson, JJ Stark, JL Granick, and D Richardson
	JCO Nov 1 1998: 3649–3655. [Abstract] [PDF]
	Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home
	S Mercadante, A Casuccio, A Agnello, R Serretta, L Calderone, and L Barresi
	JCO Nov 1 1998: 3656–3661. [Abstract] [PDF]
	Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer
	JA Sloan, CL Loprinzi, SA Kuross, AW Miser, JR O'Fallon, MR Mahoney, IM Heid, ME Bretscher, and NL Vaught
	JCO Nov 1 1998: 3662–3673. [Abstract] [PDF]
	Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
	DM Bradshaw and RJ Arceci
	JCO Nov 1 1998: 3674–3690. [Abstract] [PDF]
	Monoclonal antibody-based therapies for hematologic malignancies
	PS Multani and ML Grossbard
	JCO Nov 1 1998: 3691–3710. [Abstract] [PDF]
Large bowel mucosal metastases from breast cancer
HK van Halteren, H Peters, and PG Gerlag
JCO Nov 1 1998: 3711–3713. [PDF]
Adequate number of patients are needed to evaluate adjuvant treatment in gastric cancer
H Bleiberg, T Sahmoud, A Di Leo, D Cunningham, and P Rougier
JCO Nov 1 1998: 3714a. [PDF]
Cancer chemotherapy and body surface area
D Pinkel
JCO Nov 1 1998: 3714b–3715. [PDF]
A flat dose for all adult [sic] patients
WA Bleyer
JCO Nov 1 1998: 3715a. [PDF]
The next (third) dimension to dosing of anticancer agents
HM Vriesendorp
JCO Nov 1 1998: 3715b–3716. [PDF]
Interferon toxicity worse in retrospect; impact on Q-TWiST? Quality- Adjusted Time Without Symptoms or Toxicity
DL Longo
JCO Nov 1 1998: 3716a. [PDF]
Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients? Quality-Adjusted Time Without Symptoms or Toxicity
A Messori and S Trippoli
JCO Nov 1 1998: 3716b–3717. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.